Guardant Health in the news
advanced cancer detection technology
Tamtam found 20 recent articles about Guardant Health.
- Guardant Health (GH): Evaluating Valuation After FDA Approval Expands Guardant360 CDx Utility in Breast Cancer Care
Guardant Health's FDA approval for its breast cancer diagnostic test has driven strong stock gains and suggests modest undervaluation amid growth and risk factors.
- Guardant Health (GH): Valuation Spotlight as Quest Deal Expands Shield Test Access and Fuels Growth Optimism
Guardant Health’s partnership with Quest Diagnostics to expand its FDA-approved colorectal cancer blood test is fueling stock growth and optimism despite some valuation concerns.
- Guardant Health’s Strong Growth Trajectory and Unique Oncology Approach Earns Buy Rating
Guardant Health’s strong oncology diagnostics growth and unique epigenetics focus have led analysts to raise price targets and maintain Buy ratings despite insider selling.
- Guardant Health Hosts Investor Day in NYC
Guardant Health plans an Investor Day in NYC to discuss its cancer blood test business, financial outlook, and strategic priorities amid mixed analyst ratings.
- Quest to distribute Guardant colon cancer blood test
Guardant Health and Quest Diagnostics will collaborate to distribute the FDA-approved Shield blood test for colorectal cancer screening starting in 2026, with plans to expand it to multi-cancer detection.
- Why Guardant Health (GH) Is Up 7.8% After Strong Revenue Surge and Expanded Shield Test Access
Guardant Health's revenue surged 30.9% in 2025, expanding access to its Shield colorectal cancer blood test and adding experienced leadership, though profitability challenges remain.
- Guardant Health Director Makes Significant Stock Sale!
Guardant Health's director sold shares amid new partnerships and board appointments, while the stock fell after colorectal cancer test data slightly missed expectations.
- Alex M. Azar II Joins Guardant Health Board of Directors
Alex M. Azar II, former U.S. HHS Secretary, joined Guardant Health's board to support its precision oncology innovations and patient access efforts.
- Parkman Healthcare Partners LLC Makes New Investment in Guardant Health, Inc. $GH
Parkman Healthcare Partners and other institutional investors increased stakes in Guardant Health, which reported strong revenue growth and received positive analyst upgrades.
- Osterweis Capital Management Inc. Makes New $12.63 Million Investment in Guardant Health, Inc. $GH
Osterweis and other institutional investors increased stakes in Guardant Health, which reported strong revenue growth and received positive analyst upgrades.
- Guardant Health, Inc. $GH Shares Sold by Adalta Capital Management LLC
Guardant Health saw a modest stake reduction by Adalta Capital, reported better-than-expected Q2 revenue growth, but insiders sold shares amid a recent stock price dip.
- Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
Guardant Health and PathGroup partner to expand access to the FDA-approved Shield blood test for early colorectal cancer detection across 250+ hospitals in 25 states.
- Ieq Capital LLC Takes $660,000 Position in Guardant Health, Inc. $GH
Ieq Capital and other institutional investors increased their stakes in Guardant Health, which reported strong Q2 revenue growth and has mostly positive analyst ratings.
- Guardant Health reports positive clinical readout update for Shield algorithm
Guardant Health's Shield V2 blood test algorithm shows strong clinical performance in detecting early-stage colorectal cancer, with FDA approval for primary screening.
- Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Guardant Health will present at the Morgan Stanley Healthcare Conference, highlighting its precision oncology tests and AI-driven cancer care solutions.
- Guardant Health stock hits 52-week high at 60.69 USD
Guardant Health's stock hit a 52-week high driven by strong Q2 2025 earnings, revenue growth, and raised full-year guidance.
- Multi Cancer Early Detection Market and Forecast Report 2025-2033, with Profiles of GRAIL, Guardant Health, Illumina, Freenome, Burning Rock Biotech, AnchorDx, Genecast, Singlera Genomics, and More - ResearchAndMarkets.com | FinancialContent
The multi cancer early detection market is rapidly growing due to technological advances and rising public awareness, with revenues expected to exceed $4 billion by 2033.
- Guardant Health Director Tariq Musa Sells 116 Shares at $59.02 on 2025-08-19
Guardant Health Director Tariq Musa sold 116 vested shares at $59.02 each in a routine insider transaction on August 19, 2025.
- Guardant Health Awards Stock Options and RSUs to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health awarded stock options and RSUs to new employees under Nasdaq rules to attract and retain talent, with vesting over 24 months.
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health granted stock units and options to new employees as inducements under Nasdaq rules, supporting its precision oncology workforce expansion.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Guardant Health?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies